We are live on ! Find out more
ALNA

Allena Pharmaceuticals
ALNA

Delisted

ALNA was delisted on the 7th of September, 2022.

Back to rankings

35 hedge funds and large institutions have $59.8M invested in Allena Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

4% less capital invested

Capital invested by funds: $62.4M → $59.8M (-$2.63M)

24% less funds holding

Funds holding: 46 → 35 (-11)

73% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 15

Holders
35
Holders Change
-11
Holders Change %
-23.91%
% of All Funds
0.77%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
4
Increased
12
Reduced
11
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$784K
2
Millennium Management
Millennium Management
New York
+$682K
3
Renaissance Technologies
Renaissance Technologies
New York
+$215K
4
BlackRock
BlackRock
New York
+$165K
5
LI
LVZ Inc
Michigan
+$71.8K

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$1.3M
2
Northern Trust
Northern Trust
Illinois
-$396K
3
Morgan Stanley
Morgan Stanley
New York
-$200K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$169K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$153K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$48K +$1.88K +438 +4%
RJFSA
27
Raymond James Financial Services Advisors
Florida
$43K -$8.58K -2,000 -16%
Acadian Asset Management
28
Acadian Asset Management
Massachusetts
$37K +$40.1K +9,345 New
Barclays
29
Barclays
United Kingdom
$32K -$8.65K -2,016 -20%
UBS Group
30
UBS Group
Switzerland
$13K +$13.9K +3,231 +11,967%
MAM
31
Meeder Asset Management
Ohio
$10K +$8.61K +2,006 +456%
Victory Capital Management
32
Victory Capital Management
Texas
$7K +$7.79K +1,815 New
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$5.35K – – –
Citigroup
34
Citigroup
New York
$5K -$7.82K -1,821 -58%
PAM
35
Panagora Asset Management
Massachusetts
$3K +$3.33K +777 New
Jacobs Levy Equity Management
36
Jacobs Levy Equity Management
New Jersey
– -$169K -41,587 Closed
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
– -$137K -33,565 Closed
FI
38
Fosun International
China
– -$124K -29,877 Closed
Jane Street
39
Jane Street
New York
– -$116K -28,570 Closed
TAM
40
Tiverton Asset Management
Delaware
– -$18K -4,546 Closed
Deutsche Bank
41
Deutsche Bank
Germany
– -$13K -3,533 Closed
Legal & General Group
42
Legal & General Group
United Kingdom
– -$7K -1,728 Closed
NA
43
Neuburgh Advisers
California
– -$4K -986 Closed
TRCT
44
Tower Research Capital (TRC)
New York
– -$3K -839 Closed
FCM
45
Flinton Capital Management
Pennsylvania
– -$3K -812 Closed
TAM
46
Tyers Asset Management
Texas
– -$3K -638 Closed
CIAS
47
Capital Investment Advisory Services
North Carolina
– -$2K -500 Closed
GHCM
48
Glen Harbor Capital Management
California
– -$2K -464 Closed
PCP
49
Proficio Capital Partners
Massachusetts
– -$1K -241 Closed
1
2

ALNA Hedge Fund Activity: Q3 2019 in Review

35 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q3 2019, worth a combined $59.8M — down 4.2% from $62.4M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ALNA and 4 opened new positions — a net loss of 11 holders — while 11 trimmed existing stakes and 12 added.

The largest buyer was Sphera Funds Management, adding an estimated $784K. The largest seller was PFM Health Sciences, cutting an estimated $1.3M.

  • 35 institutional investors held Allena Pharmaceuticals (ALNA) as of Q3 2019, down from 46 in Q2 2019.
  • Funds reported $59.8M of Allena Pharmaceuticals stock for Q3 2019, down 4.2% quarter-over-quarter.
  • 4 funds opened new Allena Pharmaceuticals positions in Q3 2019 and 15 closed out, a net change of -11 holders.
  • The largest Allena Pharmaceuticals buyer in Q3 2019 was Sphera Funds Management, an estimated $784K added.
  • The largest Allena Pharmaceuticals seller in Q3 2019 was PFM Health Sciences, an estimated $1.3M sold.

Based on aggregated 13F filings for Q3 2019.